Hem­genix now ap­proved, Paul Per­reault plans his ex­it from CSL; Lian­Bio pres­i­dent hands in res­ig­na­tion

→ As CSL trends up­ward, Paul Per­reault will soon step down, putting one of his lieu­tenants in the top spot.

Paul McKen­zie, the COO at the Aus­tralian phar­ma since 2019, will be­come CSL’s chief ex­ec­u­tive on March 6, while Per­reault lends a hand in an ad­vi­so­ry ca­pac­i­ty for six more months af­ter the tran­si­tion takes ef­fect. McKen­zie owns Big Phar­ma ex­pe­ri­ence from Mer­ck, Bris­tol My­ers Squibb and J&J’s Janssen, and was Bio­gen’s EVP of phar­ma­ceu­ti­cal op­er­a­tions & tech­nol­o­gy be­fore CSL came call­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER